INSIGHTS ON DRUG DEVELOPMENT

• Enabling Quality By Design

  Outdated quality systems delay product release. Discover how manufacturers can harness real-time data, operationalize QbD, and enhance compliance, efficiency, and supply chain continuity.

• T3P – A Green Solution For Peptide Coupling, Water Removal Reactions

  The session focuses on the use of T3P (propanephosphonic acid anhydride) in amidation and peptide coupling reactions, including both liquid-phase and solid-phase peptide synthesis.

• Method Development For Forced Degradation Of GLP-1 Agonist

  Gain insight into how a systematic approach reveals impurity behavior, strengthens selectivity, and refines chromatographic conditions to build a reliable degradation method for a GLP‑1 agonist.

• How The Accelerator™ Drug Development Model Enhances eNPV

  Discover how an integrated CDMO and CRO model can accelerate development timelines, add up to $62.9 million in value, and help you maximize long-term pipeline success with a single, streamlined partner.

• Predicting Food Effects In Oral Drug Delivery Using PBPK Modeling

  7/15/2026

  Learn how integrated PBPK and molecular dynamics modeling predicted an ~11% fed-state Cmax increase for fenofibrate, giving formulation teams earlier, mechanistic insight into food-dependent absorption.

• Assessing Particle Generation In A Single-Use Mixing System

  11/13/2025

  Explore how particle levels remained stable during 24 hours of high-speed mixing, even under extreme temperatures, confirming a system’s suitability for final fill and other particulate-sensitive applications.

• White Paper: Spray Drying Biologics: An Alternative To Freeze Drying

  10/16/2024

  Explore how innovative drying technologies can enhance the stability and efficacy of biologics, ensuring successful outcomes in this rapidly growing sector of the pharmaceutical industry.

• Polymorphism 101: What Early-Stage Drug Developers Need To Know To Reduce Risk

  5/18/2026

  Polymorphism impacts solubility, stability, and manufacturability, making early solid‑form screening critical to reduce risk, guide development decisions, and ensure consistent performance.

• Overcoming Challenges In Ophthalmic Formulations Through Polymer Selection

  8/27/2025

  The growing demand for ophthalmic drugs is driven by aging populations and increased screen time, which contributes to rising eye conditions. Explore innovative solutions in ophthalmic drug development.